Search the Newsreel

Abbott Laboratories (ABT) Ties Lingo Glucose Data To AI Health Tools

Get insights on thousands of stocks from the global community of over 7 million individual investors at Simply Wall St. Abbott Laboratories (NYSE:ABT) and Google Health announced a multi year partnership to integrate Abbott's Lingo biowearable glucose data with Google's AI driven consumer health …

How ABBV Stock Moved Away From Its Peer Group

AbbVie (ABBV) has shown strong fundamental performance with high revenue growth and operating margins, yet its stock returns significantly lag behind peers like Merck and Johnson & Johnson. This disconnect is attributed to the market pricing in future competitive threats to AbbVie's key drug …

ABBOTT LABORATORIES AKTIE: AI-Analysen, Prognose & Kursziel

Abbott Laboratories stock outperforms competitors on strong trading day

Shares of Abbott Laboratories (ABT) rose 1.08% to $110.91, marking its third consecutive day of gains. This performance occurred on a mixed trading day where the S&P 500 Index increased by 0.26% and the Dow Jones Industrial Average fell by 0.04%. The stock's positive …

The Abbott Big Ten $1 Million Blood Drive is Back

The Abbott Big Ten $1 Million Blood Drive returns for its third year, with Nebraska aiming to reclaim the title from Wisconsin. The competition, which runs from August 26th to December 4th, encourages donations to help address a national blood crisis, with a $1 …

Las acciones de AbbVie enfrentan volatilidad con fortaleza en resultados, pero la resistencia sigue siendo clave: análisis semanal

What Abbott Laboratories (ABT)'s AI-Powered Google Health Partnership Means For Shareholders

Abbott Laboratories has partnered with Google Health to integrate glucose insights from its Lingo biowearable into the Google Health app, using AI for personalized metabolic health coaching and unified wellness data. This collaboration includes a large-scale metabolic health study, potentially supporting Abbott's diabetes franchise …

Abbott India Q1 net profit surges 17% despite 4% revenue growth

Every 2 Seconds, Someone in the U.S. Needs Blood as Abbott Drive Returns

Abbott (NYSE: ABT) and the Big Ten Conference have relaunched their "We Give Blood" nationwide competition to address a critical blood supply crisis in the U.S. All 18 Big Ten universities will compete to generate the most blood donations, with Abbott awarding $1 million …

Abbott India Limited Reports Earnings Results for the First Quarter Ended June 30, 2026

Abbott and Big Ten bring back 'We Give Blood' as U.S. faces blood supply crisis

"We Give Blood" brings together all 18 Big Ten® schools in a competition to drive the most blood donations and win $1 million from global healthcare company Abbott For only the second time in its history, the American Red Cross has declared a national …

AbbVie Inc. $ABBV Shares Bought by Wedge Capital Management L L P NC

Wedge Capital Management L L P NC increased its stake in AbbVie Inc. (NYSE:ABBV) by 7.5% in the second quarter, bringing its total holdings to 134,579 shares valued at $33.9 million. This comes as AbbVie reported strong quarterly results, beating EPS and revenue estimates, …

Abbott Laboratories $ABT Shares Sold by West Branch Capital LLC

West Branch Capital LLC significantly reduced its stake in Abbott Laboratories (NYSE:ABT) by 83.5% in the second quarter, selling 13,061 shares and retaining 2,576 shares worth $234,000. Despite this sell-off, institutional investors collectively own 75.18% of Abbott’s stock. Abbott reported strong Q2 earnings of …

BTIG downgrades Apogee Therapeutics stock rating after AbbVie deal

BTIG has downgraded Apogee Therapeutics Inc (NASDAQ:APGE) to Neutral from Buy after shareholders approved the company's acquisition by AbbVie Inc (NYSE:ABBV) for $10.9 billion, or $135.11 per share. This deal, which sees Apogee's stock trading near its 52-week high with a significant return, is …

Butensky & Cohen Financial Security Inc. Purchases 9,277 Shares of Abbott Laboratories $ABT

Butensky & Cohen Financial Security Inc. increased its stake in Abbott Laboratories (NYSE:ABT) by 26.9% in the second quarter, acquiring an additional 9,277 shares to own a total of 43,809 shares valued at $3.98 million. This move comes as Abbott Laboratories reported strong quarterly …

Cardinal Capital Management Inc. Buys 21,206 Shares of AbbVie Inc. $ABBV

Cardinal Capital Management Inc. increased its stake in AbbVie Inc. by 8.4% during the second quarter, purchasing an additional 21,206 shares to bring its total holdings to 273,719 shares valued at approximately $68.9 million. Institutional investors collectively own 70.23% of ABBV, and analysts maintain …

Abbott Laboratories (NYSE:ABT) Receives Consensus Rating of "Moderate Buy" from Brokerages

Abbott Laboratories (NYSE:ABT) has received a consensus "Moderate Buy" rating from twenty-six brokerages, with an average 12-month price target of $118.17. The company recently exceeded quarterly expectations with adjusted EPS of $1.31 and revenue of $12.59 billion, and announced a quarterly dividend of $0.63 …

GODSEY & GIBB, INC's AbbVie Inc(ABBV) Holding History

GODSEY & GIBB, INC holds 74,257.00 shares of AbbVie Inc (ABBV) as of June 30, 2026, valued at $18.69 million, representing 1.53% of their stock portfolio. The firm's initial trade was in Q2 2021, and they have made 9 purchases and 9 sales of …

¿Puede Abbott Laboratories (ABT) Estar 8% Infravalorada Tras Mejorar Su Previsión Anual?

Abbott Laboratories (ABT) schedules NYSE sale of stock from vested awards

Abbott Laboratories (ABT) has filed a Form 144 indicating a planned sale of 5,850 common shares through UBS Financial Services on or after August 11, 2026, on the NYSE. The shares originate from vested restricted stock awards granted on February 27, 2026, totaling 1,960, …

AbbVie (ABBV) Wins Canada Reimbursement Backing For Adult Migraine Treatment

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. AbbVie (NYSE: ABBV) received a recommendation from Canada's Drug Agency to reimburse UBRELVY for the acute treatment of migraine in adults. The decision …

AbbVie (ABBV) Gains On Botox Filing, Is The 9% Discount Still There?

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. AbbVie (ABBV) is back in focus after Allergan Aesthetics reported that the FDA accepted a supplemental Biologics License Application for Botox Cosmetic targeting masseter muscle prominence in …

AbbVie vs. CVS Health: Which Healthcare Stock Is a Better Buy in 2026?

This article compares AbbVie and CVS Health as investment opportunities in 2026, highlighting their distinct business models and risk profiles. AbbVie, a biopharmaceutical giant, is favored for its focused operations and exciting growth trajectory, particularly with its immunology portfolio. CVS Health, an integrated healthcare …

Abbott Partners With Google Health For AI-Powered Glucose Monitoring

Abbott has partnered with Google Health to integrate its Lingo continuous glucose monitor (CGM) data into the Google Health app, offering AI-driven recommendations for non-diabetic users. This collaboration aims to help users make better lifestyle choices and will involve a large-scale metabolic health study. …

Abbott to integrate Google’s AI health coach into wearable glucose monitoring tech

Abbott is partnering with Google to integrate Google's AI health coach into its Lingo wearable glucose monitoring technology. This collaboration aims to enhance the functionality of Abbott's continuous glucose monitoring system by providing users with AI-powered personalized health insights and coaching. The initiative was …

How Much Did Immunology Drugs Contribute to AbbVie's Q2 Performance?

AbbVie ABBV announced encouraging second-quarter 2026 results last month, which beat expectations for both earnings and sales. A significant portion of this growth came from the continued strength of its two blockbuster immunology medications, Skyrizi and Rinvoq, which together accounted for more than 47% …

Por que as ações da Abbott Laboratories estão subindo hoje? - Investing.com Brasil

Why is Abbott Laboratories stock gaining today?

Abbott Laboratories stock rose 1.2% after announcing a multi-year collaboration with Google Health. This partnership will integrate glucose data from Abbott's Lingo biowearable continuous glucose monitor into the Google Health app, offering personalized health recommendations. The deal also includes a large-scale metabolic health study, …

Abbott and Google launch first-of-its-kind partnership to transform everyday health through glucose insights and AI

Abbott and Google Health have announced a multi-year partnership to integrate glucose insights from Abbott's Lingo biowearable with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, helping users understand how daily behaviors affect their …

Abbott, Google to Study How Sleep and Activity Affect Glucose

Abbott has announced a multi-year partnership with Google Health to integrate insights from Abbott's Lingo continuous glucose monitor with Google's AI and consumer technology. This collaboration aims to provide personalized metabolic insights through the Google Health app, offering AI-powered guidance on nutrition, activity, sleep, …

Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices

Updated program delivers simplified savings, greater benefits transparency, and expanded opportunities for practice growth Introduces new rewards opportunities for customer segments, including first-time APP members, growing practices, and long-standing loyal customers IRVINE, Calif., Aug. 11, 2026 /PRNewswire/ -- Allergan Aesthetics, an AbbVie company, today …

Abbott Laboratories price shows more positive signals - Forecast today - 11-08-2026

Abbott Laboratories (ABT) is showing positive signals, with its stock trading above its 50-day Simple Moving Average and momentum indicators generating bullish signals. The outlook remains bullish as long as support at $102.90 holds, with a target resistance level at $114.00. This forecast suggests …

AbbVie Piles on $8 Billion in Debt for Its Apogee Deal -- Should Dividend Investors Worry?

AbbVie (NYSE: ABBV) is aiming high with its $10.6 billion planned purchase of Apogee Therapeutics (NASDAQ: APGE). The deal, pending regulatory approvals, is expected to close in the third quarter. The move is designed to supplement the pharmaceutical giant's already strong immunology portfolio. However, …

Handelsbanken Fonder AB Sells 444,592 Shares of Abbott Laboratories $ABT

Handelsbanken Fonder AB reduced its stake in Abbott Laboratories by 37.6% in the second quarter, selling 444,592 shares and retaining 736,804 shares valued at approximately $66.9 million. Abbott Laboratories reported strong quarterly results, exceeding analyst expectations with $12.59 billion in revenue and adjusted earnings …

AbbVie Inc. $ABBV Position Cut by Handelsbanken Fonder AB

Handelsbanken Fonder AB reduced its stake in AbbVie Inc. by 1.4% during the second quarter, selling 19,132 shares and now owning 1,362,464 shares worth $342.85 million. Despite this, AbbVie remains a "Moderate Buy" among analysts, with recent positive news including the acquisition of Apogee …

Abbott India shares climb over 2% to Rs 28,120.00